NTI
Neurotech Receives HREC Approval to Commence Phase I/II Cerebral Palsy Trial.
NTI164 is a proprietary drug formulation derived from a unique cannabis strain with low THC (M<0.3%) and a novel combination of cannabinoids including CBDA, CBC, CBDP, CBDB and CBN.